{"id":"tmc114-ritonavir","safety":{"commonSideEffects":[{"rate":"14-20","effect":"Diarrhea"},{"rate":"10-15","effect":"Nausea"},{"rate":"7-10","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"5-8","effect":"Abdominal pain"},{"rate":"5-8","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3182552","moleculeType":"Small molecule","molecularWeight":"720.96"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Darunavir inhibits HIV protease, an enzyme essential for processing viral polyproteins into functional components. When combined with ritonavir (a cytochrome P450 inhibitor that boosts darunavir levels), the drug achieves high plasma concentrations and potent suppression of HIV replication. This combination is effective against both wild-type and protease inhibitor-resistant HIV strains.","oneSentence":"TMC114 (darunavir) is a protease inhibitor that blocks HIV protease, preventing viral replication when boosted with ritonavir.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:55.748Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients"},{"name":"HIV-1 infection in treatment-naïve patients"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT06139796","phase":"PHASE1, PHASE2","title":"Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV","status":"WITHDRAWN","sponsor":"PENTA Foundation","startDate":"2025-02-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT03194165","phase":"","title":"Population Pharmacokinetics of Antiretroviral in Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-16","conditions":"Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed","enrollment":65},{"nctId":"NCT06747507","phase":"PHASE3","title":"Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance","status":"RECRUITING","sponsor":"University of Nairobi","startDate":"2025-09-01","conditions":"HIV-1-infection","enrollment":392},{"nctId":"NCT06799650","phase":"PHASE2","title":"Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV","status":"RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2025-01-01","conditions":"HIV Seropositivity","enrollment":40},{"nctId":"NCT02470650","phase":"PHASE4","title":"Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive","status":"WITHDRAWN","sponsor":"Juan A. Arnaiz","startDate":"2015-06","conditions":"Patient Compliance, Antiretroviral Therapy Intolerance","enrollment":""},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT04208061","phase":"PHASE1","title":"A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-18","conditions":"Healthy","enrollment":28},{"nctId":"NCT03675815","phase":"PHASE4","title":"Body Composition Sub-study of the D2EFT Trial","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-12-05","conditions":"HIV Infections","enrollment":155},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT06676410","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants","status":"RECRUITING","sponsor":"Code Pharma","startDate":"2023-07-20","conditions":"HIV, HIV Infection","enrollment":40},{"nctId":"NCT01400412","phase":"PHASE2","title":"Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-01-17","conditions":"HIV-1 Infection","enrollment":262},{"nctId":"NCT02275780","phase":"PHASE3","title":"Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-12-01","conditions":"HIV-1","enrollment":769},{"nctId":"NCT02735863","phase":"PHASE2","title":"ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2016-05","conditions":"HIV Infection","enrollment":30},{"nctId":"NCT04630002","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-10-28","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT04268472","phase":"NA","title":"Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg (\"Jonson&Jonson\", Russia)","status":"COMPLETED","sponsor":"Geropharm","startDate":"2019-06-06","conditions":"Bioequivalence","enrollment":44},{"nctId":"NCT02437110","phase":"PHASE1","title":"HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2019-04-01","conditions":"Amyotrophic Lateral Sclerosis","enrollment":122},{"nctId":"NCT01605084","phase":"PHASE3","title":"Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-30","conditions":"HIV","enrollment":""},{"nctId":"NCT02486133","phase":"PHASE3","title":"Dual Therapy With Boosted Darunavir + Dolutegravir","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-07","conditions":"HIV-Infection","enrollment":269},{"nctId":"NCT02336074","phase":"PHASE2","title":"Research In Viral Eradication of HIV Reservoirs","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-11-27","conditions":"HIV","enrollment":60},{"nctId":"NCT01423812","phase":"PHASE4","title":"DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects","status":"COMPLETED","sponsor":"Ruth M. Rothstein CORE Center","startDate":"2012-01","conditions":"HIV","enrollment":60},{"nctId":"NCT03017872","phase":"PHASE4","title":"Dolutegravir and Darunavir Evaluation in Adults Failing Therapy","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2017-11-23","conditions":"HIV Infections","enrollment":831},{"nctId":"NCT01281813","phase":"PHASE3","title":"TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2011-08-08","conditions":"HIV-1 Infections","enrollment":145},{"nctId":"NCT04425382","phase":"","title":"Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2020-03-01","conditions":"Coronavirus, COVID, Pneumonia","enrollment":400},{"nctId":"NCT00885495","phase":"PHASE1, PHASE2","title":"Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2009-01","conditions":"HIV Infections","enrollment":17},{"nctId":"NCT02269917","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2015-03","conditions":"Human Immunodeficiency Virus Type 1","enrollment":1149},{"nctId":"NCT00260078","phase":"PHASE1, PHASE2","title":"Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT00537394","phase":"PHASE3","title":"Optimizing Treatment for Treatment-Experienced, HIV-Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-01","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT04303299","phase":"PHASE3","title":"Fight COVID-19 Trial","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-08-19","conditions":"SARS-COV-2 Infections, COVID-19","enrollment":320},{"nctId":"NCT03602690","phase":"PHASE2","title":"Evaluation of Third-line cART Regimen in Cambodia (3DICAM)","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-10-04","conditions":"HIV/AIDS","enrollment":54},{"nctId":"NCT02738502","phase":"PHASE2","title":"Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-07-06","conditions":"Maternal-fetal Infection Transmission","enrollment":91},{"nctId":"NCT01232361","phase":"","title":"IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-10-08","conditions":"ADHD, HIV","enrollment":127},{"nctId":"NCT01939197","phase":"PHASE2, PHASE3","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-30","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":318},{"nctId":"NCT04475120","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"2020-04-15","conditions":"Covid19","enrollment":92},{"nctId":"NCT02383108","phase":"PHASE2, PHASE3","title":"Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2016-06","conditions":"HIV Infection","enrollment":318},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT04386447","phase":"PHASE2","title":"Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19","status":"WITHDRAWN","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2020-09-01","conditions":"Covid-19, Corona Virus Infection, SARS-CoV 2","enrollment":""},{"nctId":"NCT04435587","phase":"PHASE4","title":"Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-07-13","conditions":"Asymptomatic Infections, SARS-CoV2 Infection","enrollment":80},{"nctId":"NCT03472326","phase":"PHASE2","title":"Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2018-04-03","conditions":"HIV-1-infection","enrollment":21},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT02285478","phase":"","title":"Pharmacokinetics of Once Daily Darunavir/Ritonavir in HIV-infected Children","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-03","conditions":"Human Immunodeficiency Virus, Children","enrollment":12},{"nctId":"NCT04183738","phase":"PHASE4","title":"Inflammation and Co-Infections in D²EFT","status":"WITHDRAWN","sponsor":"Kirby Institute","startDate":"2021-02-01","conditions":"HIV-infection/Aids, Human Herpesvirus 4 Infections, Cytomegalovirus Infections","enrollment":""},{"nctId":"NCT03198884","phase":"","title":"A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir","status":"COMPLETED","sponsor":"Southern Illinois Healthcare Foundation","startDate":"2017-01-01","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT00925756","phase":"PHASE4","title":"CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-10-20","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT01695954","phase":"PHASE1","title":"Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2012-05","conditions":"Hyperlipidemia, HIV","enrollment":34},{"nctId":"NCT03988452","phase":"PHASE3","title":"Nucleosides And Darunavir/Dolutegravir In Africa","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2019-07-30","conditions":"Human Immunodeficiency Virus","enrollment":465},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT04388514","phase":"NA","title":"Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure","status":"UNKNOWN","sponsor":"Azienda Sanitaria-Universitaria Integrata di Udine","startDate":"2020-04-08","conditions":"SARS-CoV-2 Respiratory Failure","enrollment":90},{"nctId":"NCT04368351","phase":"","title":"Bacteriotherapy in the Treatment of COVID-19","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2020-03-01","conditions":"COVID, Pneumonia, Diarrhea","enrollment":70},{"nctId":"NCT04366089","phase":"PHASE2","title":"Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora","status":"UNKNOWN","sponsor":"Roberto Poscia MD, PhD","startDate":"2020-03-26","conditions":"COVID, SARS-CoV 2, Pneumonia, Viral","enrollment":152},{"nctId":"NCT01792570","phase":"PHASE3","title":"DRV/r + RPV QD: Efficacy and Toxicity Reduction","status":"COMPLETED","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2014-09-30","conditions":"Human Immunodeficiency Virus","enrollment":37},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT01869634","phase":"PHASE4","title":"Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2013-06","conditions":"Human Immunodeficiency Virus Infection","enrollment":37},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT00611039","phase":"PHASE4","title":"Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2008-02","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01046890","phase":"PHASE4","title":"Drug Interactions Between Echinacea Purpurea and Darunavir/Ritonavir","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2010-01","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV Infections","enrollment":675},{"nctId":"NCT01346982","phase":"PHASE4","title":"Drug Interactions Between Silimarine and Darunavir/Ritonavir","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2011-03","conditions":"HIV","enrollment":15},{"nctId":"NCT01348763","phase":"PHASE1","title":"The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-10","conditions":"HIV","enrollment":13},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01367236","phase":"PHASE4","title":"Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-01","conditions":"HIV, Impaired Cognition","enrollment":60},{"nctId":"NCT01258374","phase":"","title":"Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2010-05","conditions":"Integrase Inhibitors, HIV; HIV PROTEASE INHIB","enrollment":15},{"nctId":"NCT02155101","phase":"PHASE3","title":"Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2014-05","conditions":"HIV/AIDS","enrollment":120},{"nctId":"NCT01138605","phase":"PHASE2","title":"TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2010-10-13","conditions":"HIV-1 Infections","enrollment":46},{"nctId":"NCT01900106","phase":"PHASE3","title":"A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)","status":"COMPLETED","sponsor":"University of Modena and Reggio Emilia","startDate":"2013-11","conditions":"HIV Infection","enrollment":47},{"nctId":"NCT02116660","phase":"PHASE2","title":"Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT03892161","phase":"PHASE1","title":"Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers","status":"TERMINATED","sponsor":"University of Cape Town","startDate":"2018-04-12","conditions":"HIV Infections","enrollment":17},{"nctId":"NCT03589027","phase":"PHASE2","title":"Darunavir and Rilpivirine Interactions With Levonorgestrel Implant","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2018-08-07","conditions":"HIV-1-infection, Contraception","enrollment":60},{"nctId":"NCT03589040","phase":"PHASE2","title":"Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2018-09-25","conditions":"HIV, Contraception","enrollment":60},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT00823979","phase":"PHASE2","title":"A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-03-25","conditions":"HIV-1","enrollment":105},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00830804","phase":"PHASE2","title":"Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-04","conditions":"HIV-1 Infections","enrollment":113},{"nctId":"NCT02489487","phase":"PHASE1","title":"Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500","status":"COMPLETED","sponsor":"Viriom","startDate":"2014-09","conditions":"HIV-infection","enrollment":24},{"nctId":"NCT01923311","phase":"PHASE2, PHASE3","title":"Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-08-26","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":31},{"nctId":"NCT02337322","phase":"PHASE4","title":"Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir","status":"UNKNOWN","sponsor":"Juan A. Arnaiz","startDate":"2015-03-31","conditions":"Acquired Immune Deficiency Syndrome Virus","enrollment":104},{"nctId":"NCT02770508","phase":"PHASE4","title":"Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2015-11","conditions":"HIV-1 Infection","enrollment":145},{"nctId":"NCT00855335","phase":"PHASE3","title":"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2009-04-09","conditions":"HIV, HIV Infections, Pregnancy","enrollment":77},{"nctId":"NCT02671383","phase":"PHASE3","title":"Evaluation of Low-dose Darunavir in a Switch Study","status":"COMPLETED","sponsor":"Willem Daniel Francois Venter","startDate":"2016-06-30","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT02926456","phase":"","title":"Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2016-07-22","conditions":"Human Immunodeficiency Virus","enrollment":337},{"nctId":"NCT01449929","phase":"PHASE3","title":"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-10-31","conditions":"Infection, Human Immunodeficiency Virus","enrollment":488},{"nctId":"NCT01928407","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts","status":"COMPLETED","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2011-02-23","conditions":"HIV-1 Infection, Immunosuppression-related Infectious Disease","enrollment":120},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT01448707","phase":"PHASE3","title":"A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-03-15","conditions":"Human Immunodeficiency Virus (HIV) Infections, Acquired Immunodeficiency Syndrome (AIDS) Virus","enrollment":274},{"nctId":"NCT01199731","phase":"PHASE2","title":"Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-10-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT00855413","phase":"PHASE4","title":"HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-03","conditions":"Acute HIV Infection, HIV Infections","enrollment":15},{"nctId":"NCT00756730","phase":"PHASE4","title":"Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-09","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT02154360","phase":"PHASE1","title":"Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-05","conditions":"HIV Infection","enrollment":12},{"nctId":"NCT02063360","phase":"PHASE1","title":"DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-02-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":42},{"nctId":"NCT00543101","phase":"PHASE4","title":"Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2007-10","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT00936793","phase":"PHASE1","title":"Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2009-07-06","conditions":"HIV, Asthma","enrollment":53},{"nctId":"NCT01736761","phase":"PHASE4","title":"A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2012-12","conditions":"HIV","enrollment":36},{"nctId":"NCT02513147","phase":"PHASE4","title":"HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-06","conditions":"HIV-1","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PI"],"phase":"marketed","status":"active","brandName":"TMC114/ritonavir","genericName":"TMC114/ritonavir","companyName":"Janssen-Cilag Ltd.","companyId":"janssen-cilag-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TMC114 (darunavir) is a protease inhibitor that blocks HIV protease, preventing viral replication when boosted with ritonavir. Used for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naïve patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}